What is Triastek?
Founded in 2015 by Dr. Senping Cheng and Dr. Xiaoling Li, Triastek operates at the intersection of biotechnology and advanced engineering. The company specializes in a proprietary 3D printing pharmaceutical platform that enables precise control over drug release profiles and dosage forms. By utilizing both in-house product development and strategic co-development models with multinational pharmaceutical entities, Triastek is effectively redefining the standards for intelligent manufacturing in the life sciences sector. Their market position is characterized by a commitment to innovation, aiming to establish a new paradigm for global pharmaceutical production efficiency and patient-centric therapeutic solutions.
How much funding has Triastek raised?
Triastek has raised a total of $85.4M across 3 funding rounds:
Series A
$15M
Series B
$50M
Other Financing Round
$20.4M
Series A (2020): $15M with participation from Zheng Xiaodong, Dalton Venrures, Shangahi Tofflon Science, and Yunqi Partners
Series B (2021): $50M led by CPE, Morningside Ventures, Dalton Venture, Matrix Partners China, and Shanghai Sci-Tech Innovation Center Capital
Other Financing Round (2023): $20.4M supported by Jiangsu Guoxin Investment Group
Key Investors in Triastek
Jiangsu Guoxin Investment Group
A large-scale state-owned group company authorized by the Jiangsu provincial government, focusing on energy, financial services, and strategic asset management.
Dalton Venture
A venture capital firm specializing in early-stage investments and industrial mergers within the health sector, with a focus on innovative medical technologies.
Matrix Partners China
A prominent venture capital firm that partners with founders to build high-growth companies, providing deep operational expertise and global resources.
What's next for Triastek?
With the recent influx of capital, Triastek is well-positioned to accelerate its clinical pipeline and expand its manufacturing footprint. The company's strategic roadmap involves deepening its collaborative efforts with top-tier pharmaceutical partners to bring 3D-printed dosage forms to the global market. As the industry shifts toward personalized medicine and precision manufacturing, Triastek's ability to scale its technology will be critical. Future growth will likely focus on regulatory milestones, the expansion of its intelligent manufacturing facilities, and the continued refinement of its proprietary printing technology to meet the evolving demands of the international healthcare landscape.
See full Triastek company page
